NIAID | Technology Transfer

NEUTRALIZING ANTIBODIES TO HIV-1 ENV AND THEIR USE

Read more about NEUTRALIZING ANTIBODIES TO HIV-1 ENV AND THEIR USE

China
201980025868.8
Filed on 2019-02-21

NEUTRALIZING ANTIBODIES TO HIV-1 ENV AND THEIR USE

Read more about NEUTRALIZING ANTIBODIES TO HIV-1 ENV AND THEIR USE

Canada
3091437
Filed on 2019-02-21

NEUTRALIZING ANTIBODIES TO HIV-1 ENV AND THEIR USE

Read more about NEUTRALIZING ANTIBODIES TO HIV-1 ENV AND THEIR USE

Australia
2019226034
Filed on 2019-02-21

COMPOSITIONS AND METHODS OF MANUFACTURING STAR POLYMERS FOR LIGAND DISPLAY AND/OR DRUG DELIVERY

Read more about COMPOSITIONS AND METHODS OF MANUFACTURING STAR POLYMERS FOR LIGAND DISPLAY AND/OR DRUG DELIVERY

Patent Cooperation Treaty
PCT/US2020/028586
Filed on 2020-04-16

CD153 AND/OR CD30 IN INFECTION

Read more about CD153 AND/OR CD30 IN INFECTION

US Application 16/971,144
Filed on 2020-08-19

MYELIN OLIGODENDROCYTE GLYCOPROTEIN, MYELIN BASIC PROTEIN, AND PROTEOLIPID PROTEIN COMPOSITIONS AND METHODS OF USE

Read more about MYELIN OLIGODENDROCYTE GLYCOPROTEIN, MYELIN BASIC PROTEIN, AND PROTEOLIPID PROTEIN COMPOSITIONS AND METHODS OF USE

US Application 16/934,573
Filed on 2020-07-21

EPSTEIN-BARR VIRUS VACCINES

Read more about EPSTEIN-BARR VIRUS VACCINES

US Patent 12,005,115
Filed on 2020-07-07

TREATMENT OF INFECTIONS AND IMMUNE DYSREGULATION IN PATIENTS WITH PRIMARY IMMUNE DEFICIENCIES USING MRNA-CORRECTED AUTOLOGOUS GRANULOCYTES, LYMPHOCYTES AND/OR NATURAL KILLER CELLS

Read more about TREATMENT OF INFECTIONS AND IMMUNE DYSREGULATION IN PATIENTS WITH PRIMARY IMMUNE DEFICIENCIES USING MRNA-CORRECTED AUTOLOGOUS GRANULOCYTES, LYMPHOCYTES AND/OR NATURAL KILLER CELLS

US Application 16/968,792
Filed on 2020-08-10

TREATMENT OF INFECTIONS AND IMMUNE DYSREGULATION IN PATIENTS WITH PRIMARY IMMUNE DEFICIENCIES USING MRNA-CORRECTED AUTOLOGOUS GRANULOCYTES, LYMPHOCYTES AND/OR NATURAL KILLER CELLS

Read more about TREATMENT OF INFECTIONS AND IMMUNE DYSREGULATION IN PATIENTS WITH PRIMARY IMMUNE DEFICIENCIES USING MRNA-CORRECTED AUTOLOGOUS GRANULOCYTES, LYMPHOCYTES AND/OR NATURAL KILLER CELLS

European Patent
19709243.0
Filed on 2019-02-19

VACCINE CANDIDATES FOR HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) HAVING ATTENUATED PHENOTYPES

Read more about VACCINE CANDIDATES FOR HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) HAVING ATTENUATED PHENOTYPES

US Patent 11,390,651
Filed on 2020-08-31

Subscribe to NIAID